Daimon Tatsuaki, Kosaka Takeo, Hongo Hiroshi, Aimono Eriko, Nakamura Kohei, Mikami Shuji, Nishihara Hiroshi, Oya Mototsugu
Department of Urology Keio University School of Medicine Tokyo Japan.
Genomics Unit Keio Cancer Center Keio University School of Medicine Tokyo Japan.
IJU Case Rep. 2021 May 5;4(4):216-219. doi: 10.1002/iju5.12287. eCollection 2021 Jul.
Genomic profiling provides useful information for diagnosis, treatment, and prognosis, and detection of certain defects, such as DNA repair gene aberrations or microsatellite instability, can possibly lead to optimal treatment, but this testing has not been widely used to inform prostate cancer treatment.
A 55-year-old man sequentially treated for prostate cancer was diagnosed as neuroendocrine prostate cancer from prostate specimens resected because of urinary retention. Subsequently, he received five cycles of platinum-based chemotherapy in total and responded well. We also performed next-generation sequencing of a sample from the prostate specimen and identified a mutation with amplification and loss of heterozygosity in .
We report a neuroendocrine prostate cancer patient with amplification who experienced an aggressive course and for whom platinum-based chemotherapy was effective, and one of the reasons for the good response might be the mutation.
基因组分析为诊断、治疗和预后提供了有用信息，检测某些缺陷，如DNA修复基因畸变或微卫星不稳定性，可能会带来最佳治疗方案，但这种检测尚未广泛应用于指导前列腺癌的治疗。
一名55岁的前列腺癌患者因尿潴留接受前列腺切除标本检查，被诊断为神经内分泌前列腺癌。随后，他总共接受了五个周期的铂类化疗，反应良好。我们还对前列腺标本的一个样本进行了二代测序，发现了一个 突变，伴有 扩增和杂合性缺失。
我们报告了一名患有 扩增的神经内分泌前列腺癌患者，其病程进展迅速，铂类化疗有效，良好反应的原因之一可能是 突变。
